American Society of Transplantation and Cellular Therapy Series: #7-Management of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients

The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy (ASTCT) partnered with its Transplant Infectious Disease Special Interest Group (TID-SIG) to update the 2009 compendium-style infectious disease guidelines for hematopoietic cell transplantation (HCT). A new approach was adopted to better serve clinical providers by publishing each standalone topic in the infectious disease series in a concise format of frequently asked questions (FAQ), tables, and figures. Experts in HCT and infectious diseases identified FAQs and then provided answers based on the strength of the recommendation and the level of supporting evidence. In the seventh guideline in the series, we focus on the respiratory syncytial virus (RSV) with FAQs addressing epidemiology, clinical diagnosis, prophylaxis, and treatment. Special consideration was given to RSV in pediatric, cord blood, haploidentical, and T cell-depleted HCT and chimeric antigen receptor T cell therapy recipients, as well as to identify future research directions.(c) 2023 The American Society for Transplantation and Cellular Therapy. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Automated summary

The Practice Guidelines Committee of the American Society of Transplantation and Cellular Therapy partnered with its Transplant Infectious Disease Special Interest Group to update the guidelines for hematopoietic cell transplantation. They adopted a new approach of publishing each topic in a concise format of FAQs, tables, and figures. In the seventh guideline, they focused on respiratory syncytial virus (RSV) and provided answers to FAQs regarding epidemiology, clinical diagnosis, prophylaxis, and treatment.